MIMEDX GROUP INC (MDXG) Fundamental Analysis & Valuation

NASDAQ:MDXG • US6024961012

Current stock price

4.12 USD
-0.05 (-1.2%)
At close:
4.11 USD
-0.01 (-0.24%)
After Hours:

This MDXG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. MDXG Profitability Analysis

1.1 Basic Checks

  • In the past year MDXG was profitable.
  • MDXG had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
  • In multiple years MDXG reported negative operating cash flow during the last 5 years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • MDXG's Return On Assets of 14.18% is amongst the best of the industry. MDXG outperforms 94.78% of its industry peers.
  • With an excellent Return On Equity value of 18.94%, MDXG belongs to the best of the industry, outperforming 95.36% of the companies in the same industry.
  • MDXG has a Return On Invested Capital of 16.82%. This is amongst the best in the industry. MDXG outperforms 96.71% of its industry peers.
  • MDXG had an Average Return On Invested Capital over the past 3 years of 16.63%. This is below the industry average of 19.64%.
  • The last Return On Invested Capital (16.82%) for MDXG is above the 3 year average (16.63%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 14.18%
ROE 18.94%
ROIC 16.82%
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • MDXG has a better Profit Margin (11.60%) than 91.30% of its industry peers.
  • The Operating Margin of MDXG (15.26%) is better than 92.46% of its industry peers.
  • In the last couple of years the Operating Margin of MDXG has grown nicely.
  • With an excellent Gross Margin value of 82.56%, MDXG belongs to the best of the industry, outperforming 86.07% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
Industry RankSector Rank
OM 15.26%
PM (TTM) 11.6%
GM 82.56%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MDXG Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MDXG is creating value.
  • The number of shares outstanding for MDXG has been increased compared to 1 year ago.
  • Compared to 5 years ago, MDXG has more shares outstanding
  • Compared to 1 year ago, MDXG has an improved debt to assets ratio.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MDXG has an Altman-Z score of 6.73. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 6.73, MDXG is doing good in the industry, outperforming 77.56% of the companies in the same industry.
  • The Debt to FCF ratio of MDXG is 0.25, which is an excellent value as it means it would take MDXG, only 0.25 years of fcf income to pay off all of its debts.
  • MDXG's Debt to FCF ratio of 0.25 is amongst the best of the industry. MDXG outperforms 95.74% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that MDXG is not too dependend on debt financing.
  • MDXG has a Debt to Equity ratio (0.06) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.25
Altman-Z 6.73
ROIC/WACC1.89
WACC8.91%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 4.32 indicates that MDXG has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.32, MDXG is in line with its industry, outperforming 50.29% of the companies in the same industry.
  • MDXG has a Quick Ratio of 3.92. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
  • MDXG has a Quick ratio of 3.92. This is comparable to the rest of the industry: MDXG outperforms 49.13% of its industry peers.
Industry RankSector Rank
Current Ratio 4.32
Quick Ratio 3.92
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDXG Growth Analysis

3.1 Past

  • MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.38%, which is quite impressive.
  • Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 19.99% in the last year.
  • MDXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.02% yearly.
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%

3.2 Future

  • Based on estimates for the next years, MDXG will show a small growth in Earnings Per Share. The EPS will grow by 1.82% on average per year.
  • The Revenue is expected to grow by 4.92% on average over the next years.
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue Next Year-14.71%
Revenue Next 2Y-1.76%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

6

4. MDXG Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.05, the valuation of MDXG can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 96.52% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.23. MDXG is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 35.64 indicates a quite expensive valuation of MDXG.
  • 91.49% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of MDXG to the average of the S&P500 Index (23.28), we can say MDXG is valued expensively.
Industry RankSector Rank
PE 10.05
Fwd PE 35.64
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 98.07% of the companies in the same industry are more expensive than MDXG, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 98.07% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.39
EV/EBITDA 5.98
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • The decent profitability rating of MDXG may justify a higher PE ratio.
  • A cheap valuation may be justified as MDXG's earnings are expected to decrease with -7.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDXG Dividend Analysis

5.1 Amount

  • No dividends for MDXG!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDXG Fundamentals: All Metrics, Ratios and Statistics

MIMEDX GROUP INC

NASDAQ:MDXG (3/20/2026, 8:08:01 PM)

After market: 4.11 -0.01 (-0.24%)

4.12

-0.05 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners73.14%
Inst Owner Change0.19%
Ins Owners1.74%
Ins Owner Change1.48%
Market Cap612.11M
Revenue(TTM)418.63M
Net Income(TTM)48.58M
Analysts81.67
Price Target9.86 (139.32%)
Short Float %4.6%
Short Ratio6.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.4%
Min EPS beat(2)16.71%
Max EPS beat(2)110.08%
EPS beat(4)4
Avg EPS beat(4)53.83%
Min EPS beat(4)6.95%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)37.48%
EPS beat(12)11
Avg EPS beat(12)67.57%
EPS beat(16)12
Avg EPS beat(16)46.59%
Revenue beat(2)2
Avg Revenue beat(2)13.43%
Min Revenue beat(2)8.43%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)8.47%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)4.52%
Revenue beat(12)10
Avg Revenue beat(12)4.59%
Revenue beat(16)12
Avg Revenue beat(16)3.74%
PT rev (1m)-7.05%
PT rev (3m)-20.76%
EPS NQ rev (1m)-180%
EPS NQ rev (3m)-180%
EPS NY rev (1m)3.03%
EPS NY rev (3m)-53.74%
Revenue NQ rev (1m)-27.28%
Revenue NQ rev (3m)-27.28%
Revenue NY rev (1m)-12.3%
Revenue NY rev (3m)-16.5%
Valuation
Industry RankSector Rank
PE 10.05
Fwd PE 35.64
P/S 1.46
P/FCF 8.39
P/OCF 8.27
P/B 2.39
P/tB 2.75
EV/EBITDA 5.98
EPS(TTM)0.41
EY9.95%
EPS(NY)0.12
Fwd EY2.81%
FCF(TTM)0.49
FCFY11.92%
OCF(TTM)0.5
OCFY12.09%
SpS2.82
BVpS1.73
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.99
Profitability
Industry RankSector Rank
ROA 14.18%
ROE 18.94%
ROCE 22.95%
ROIC 16.82%
ROICexc 41.72%
ROICexgc 59.54%
OM 15.26%
PM (TTM) 11.6%
GM 82.56%
FCFM 17.43%
ROA(3y)16.58%
ROA(5y)3.91%
ROE(3y)24.51%
ROE(5y)1.29%
ROIC(3y)16.63%
ROIC(5y)N/A
ROICexc(3y)34.07%
ROICexc(5y)N/A
ROICexgc(3y)46.74%
ROICexgc(5y)N/A
ROCE(3y)22.68%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y2.46%
ROICexc growth 3YN/A
ROICexc growth 5Y12.11%
OM growth 3YN/A
OM growth 5Y20.19%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.24%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.22
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.25
Debt/EBITDA 0.21
Cap/Depr 6.94%
Cap/Sales 0.25%
Interest Coverage 51.27
Cash Conversion 93.95%
Profit Quality 150.21%
Current Ratio 4.32
Quick Ratio 3.92
Altman-Z 6.73
F-Score5
WACC8.91%
ROIC/WACC1.89
Cap/Depr(3y)32.56%
Cap/Depr(5y)46.17%
Cap/Sales(3y)0.47%
Cap/Sales(5y)0.75%
Profit Quality(3y)118.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-71.81%
EPS Next 2Y-23.81%
EPS Next 3Y-7.32%
EPS Next 5Y1.82%
Revenue 1Y (TTM)19.99%
Revenue growth 3Y16.06%
Revenue growth 5Y11.02%
Sales Q2Q%27.11%
Revenue Next Year-14.71%
Revenue Next 2Y-1.76%
Revenue Next 3Y2.1%
Revenue Next 5Y4.92%
EBIT growth 1Y26.23%
EBIT growth 3YN/A
EBIT growth 5Y33.44%
EBIT Next Year-15.56%
EBIT Next 3Y15.13%
EBIT Next 5Y12.86%
FCF growth 1Y13.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.79%
OCF growth 3YN/A
OCF growth 5YN/A

MIMEDX GROUP INC / MDXG Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?

ChartMill assigns a fundamental rating of 6 / 10 to MDXG.


Can you provide the valuation status for MIMEDX GROUP INC?

ChartMill assigns a valuation rating of 6 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Fairly Valued.


What is the profitability of MDXG stock?

MIMEDX GROUP INC (MDXG) has a profitability rating of 7 / 10.


What is the financial health of MIMEDX GROUP INC (MDXG) stock?

The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.


What is the earnings growth outlook for MIMEDX GROUP INC?

The Earnings per Share (EPS) of MIMEDX GROUP INC (MDXG) is expected to decline by -71.81% in the next year.